Sucampo Pharmaceuticals (SCMP) Rating Lowered to Hold at Maxim Group

Maxim Group lowered shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) from a buy rating to a hold rating in a research report sent to investors on Tuesday, MarketBeat Ratings reports.

Other equities research analysts have also issued research reports about the company. Zacks Investment Research raised Sucampo Pharmaceuticals from a hold rating to a buy rating and set a $11.00 target price for the company in a research note on Tuesday, October 17th. UBS Group lowered their target price on Sucampo Pharmaceuticals from $19.00 to $15.00 and set a buy rating for the company in a research note on Thursday, October 12th. B. Riley boosted their target price on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the company a buy rating in a research note on Wednesday, December 6th. BidaskClub raised Sucampo Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, December 5th. Finally, ValuEngine raised Sucampo Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, December 1st. Four research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. Sucampo Pharmaceuticals has a consensus rating of Buy and a consensus target price of $21.00.

Shares of Sucampo Pharmaceuticals (SCMP) opened at $17.95 on Tuesday. Sucampo Pharmaceuticals has a 52 week low of $9.30 and a 52 week high of $18.10. The company has a quick ratio of 4.46, a current ratio of 5.11 and a debt-to-equity ratio of 7.37. The firm has a market capitalization of $838.28, a PE ratio of -5.46, a PEG ratio of 5.35 and a beta of 1.47.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The company had revenue of $61.27 million during the quarter, compared to analyst estimates of $58.05 million. During the same quarter in the previous year, the company posted $0.30 EPS. Sucampo Pharmaceuticals’s revenue for the quarter was up 5.9% on a year-over-year basis. analysts expect that Sucampo Pharmaceuticals will post 1.12 earnings per share for the current year.

In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the transaction, the insider now owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 4.13% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SCMP. JPMorgan Chase & Co. purchased a new position in shares of Sucampo Pharmaceuticals during the 2nd quarter worth approximately $117,000. Pinnacle Associates Ltd. purchased a new position in shares of Sucampo Pharmaceuticals during the 2nd quarter worth approximately $122,000. Trexquant Investment LP purchased a new position in shares of Sucampo Pharmaceuticals during the 3rd quarter worth approximately $122,000. SG Americas Securities LLC grew its holdings in shares of Sucampo Pharmaceuticals by 5.6% during the 2nd quarter. SG Americas Securities LLC now owns 11,977 shares of the biopharmaceutical company’s stock worth $126,000 after acquiring an additional 631 shares during the period. Finally, Nine Chapters Capital Management LLC purchased a new position in shares of Sucampo Pharmaceuticals during the 3rd quarter worth approximately $127,000. 65.29% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/30/sucampo-pharmaceuticals-scmp-rating-lowered-to-hold-at-maxim-group.html.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Analyst Recommendations for Sucampo Pharmaceuticals (NASDAQ:SCMP)

What are top analysts saying about Sucampo Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sucampo Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit